SCHEMBL3989206

SCHEMBL3989206

CCC(CN)C(=O)OC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3991422 1.00
SCHEMBL3989203 1.00
Hydrochloric Acid SCHEMBL5566160 0.98 CA1 (0.55)
SCHEMBL1627445 0.87
Hydrochloric Acid SCHEMBL661205 0.85 CA1 (0.45)
SCHEMBL184812 0.85
Hydrochloric Acid SCHEMBL28089024 0.82 CA2 (0.64)
SCHEMBL4845983 0.82 CA2 (0.64)
SCHEMBL28089225 0.82 CA2 (0.64)
SCHEMBL2706951 0.81 CPB2 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103159660-B (2R)-1-(2-methyl-3-(methoxyl group (methyl) amino)-propiono) pyrrolidine-2-carboxylic acid and application thereof 天津市国际生物医药联合研究院 2016-07-06 CN claimed
CN-103159660-A (2R)-1-(2-methyl-3-(methoxy(methyl)amino)-propionyl)pyrrolidine-2-carboxylic acid and application thereof TIANJIN INT JOINT ACADEMY BIOTECHNOLOGY & MEDICINE 2013-06-19 CN claimed
US-12351575-B2 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection HOFFMANN-LA ROCHE INC. (US) 2025-07-08 US disclosed
US-20200317660-A1 Quinazolinone Compound and Application Thereof Luoxin Healthcare Science and Technology Development (Beijing) Ltd. (CN) 2020-10-08 US disclosed
US-20200062753-A1 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection HOFFMANN-LA ROCHE INC. (US) 2020-02-27 US disclosed
US-10428069-B2 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection HOFFMANN-LA ROCHE INC. (US) 2019-10-01 US disclosed
CN-109232613-A For treating and preventing the condensed heteroaryl dihydro-pyrimidin of hepatitis b virus infected new 6- 豪夫迈·罗氏有限公司 2019-01-18 CN disclosed
EP-3114128-B1 NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN LA ROCHE (CH) 2019-01-02 EP disclosed
US-20180370969-A1 Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection HOFFMANN-LA ROCHE INC. (US) 2018-12-27 US disclosed
CN-106061978-B Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infections 豪夫迈·罗氏有限公司 2018-10-23 CN disclosed
US-10081627-B2 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection HOFFMANN-LA ROCHE INC. (US) 2018-09-25 US disclosed
US-20090291938-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-26 US disclosed
WO-2009067547-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-05-28 WO disclosed
CN-1926241-A Process for preparing enantiomerically enriched beta-2-amino acids using enzymes DSM IP ASSETS BV (NL) 2007-03-07 CN disclosed
EP-1745137-A1 ENZYMATIC PREPARATION OF AN ENANTIOMERICALLY ENRICHED BETA-2-AMINO ACIDS DSMIP Assets B.V. (NL) 2007-01-24 EP disclosed
WO-2005085462-A1 ENZYMATIC PREPARATION OF AN ENANTIOMERICALLY ENRICHED BETA-2-AMINO ACIDS DSM IP ASSETS B.V. (NL) 2005-09-15 WO disclosed
WO-2002066417-A1 METHOD FOR THE PRODUCTION OF THE ENANTIOMERS OF 2-SUBSTITUTED BETA AMINO ACIDS CHIROBLOCK GMBH (DE) 2002-08-29 WO disclosed
US-5939398-A ANTIATHEROSCLEROSIS AGENTS PFIZER INC. (US) 1999-08-17 US disclosed
EP-0737202-A1 HYPOCHOLESTEROLEMIC AGENTS PFIZER INC. (US) 1996-10-16 EP disclosed
WO-1995018143-A1 HYPOCHOLESTEROLEMIC AGENTS PFIZER INC. (US) 1995-07-06 WO disclosed